Clinical Advances in Hematology & OncologyCases in the Management of Metastatic CRC: Regorafenib as 2L Therapy After FOLFOXIRI + Bevacizumab in a Patient With a KRAS Mutation

The case reported is based on a 53-year-old woman who presented to her gastroenterologist with symptoms of bowel obstruction and right upper quadrant pain. Based on her age and excellent performance status, aggressive treatment with a triplet chemotherapy regimen of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (FOLFOXIRI) in combination with the anti–vascular endothelial growth factor receptor antibody bevacizumab was begun.